Rajendra, A., Smith, E., Perusini, M. A., Tang, K., Atenafu, E., Bankar, A., Chan, S., Davidson, M., Gupta, V., Maze, D., Minden, M. D., Richard-Carpentier, G., Schimmer, A., Schuh, A. C., Yee, K. W., Sibai, H. A. (2025). Who benefits from gilteritinib combination therapy amongst FLT3
            <sup>mut</sup>
            R/R AML? Genomic insights.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e18522